Global Ankylosing Spondylitis Market Size To Exceed USD 12.03 Billion by 2035 | CAGR of 5.86% : Market Study Report

• As per Spherical Insights & Consulting, The Global Ankylosing Spondylitis Market Size is Expected To Grow from USD 6.15 Billion in 2024 to USD 12.03 Billion by 2035, at a CAGR of 6.29% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases.

 

• The leading Ankylosing Spondylitis Market Companies such as AbbVie, Novartis, Pfizer, Eli Lilly, Johnson & Johnson, Merck & Co., UCB Pharma, Amgen, Bristol Myers Squibb, Roche, AstraZeneca, Boehringer Ingelheim, Takeda, Biogen, Sanofi, and Others.

 

 

Ankylosing Spondylitis Treatment Market: Understanding and Treatment Algorithm:

Ankylosing Spondylitis Market Size is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. It causes stiffness, pain, and eventual fusion of the spine, reducing mobility. It typically begins in early adulthood and is more common in men. The condition is autoimmune and progresses gradually over time.

 

Ankylosing Spondylitis Diagnosis:

Diagnosis involves clinical evaluation of symptoms such as chronic back pain and stiffness, especially in the morning. Imaging tests like X rays or MRI are used to detect inflammation or joint damage. Blood tests may check for markers like HLA B27, commonly associated with the disease, though not present in all patients.

 

Ankylosing Spondylitis Treatment:

Treatment aims to reduce pain, improve mobility, and slow disease progression. Nonsteroidal anti inflammatory drugs (NSAIDs) are typically first line. For moderate to severe cases, biologics such as TNF or IL 17 inhibitors are used. Physical therapy and regular exercise also play a crucial role in managing symptoms and maintaining flexibility.

 

Ankylosing Spondylitis Epidemiology:

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Ankylosing Spondylitis, Gender specific Diagnosed Incidence of Ankylosing Spondylitis, Type specific Diagnosed Incidence of Ankylosing Spondylitis, Age specific Diagnosed Incidence of Ankylosing Spondylitis, Diagnosed Incident Population based on Primary Site of Ankylosing Spondylitis, and Diagnosed Incident Population based on Histologic Classification of Ankylosing Spondylitis Tumour in the global market covering North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.

 

Principal Insights:

This section offers a global overview of Ankylosing Spondylitis epidemiology in major markets worldwide.

 

Country Wise Ankylosing Spondylitis Multiforme Epidemiology:

• The epidemiology segment provides Ankylosing Spondylitis prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.

 

Ankylosing Spondylitis: Recent Developments:

• In June 2023, Novartis announced that the European Commission had approved Cosentyx (secukinumab) for use in adult patients with moderate to severe hidradenitis suppurativa who had not responded to conventional treatments. This approval marked Cosentyx as the first IL 17A inhibitor biologic for HS in Europe, based on robust Phase III trial data.

 

Ankylosing Spondylitis Marketed Drugs:

•             Humira: AbbVie

 

Humira (adalimumab) is a TNF alpha inhibitor used to reduce inflammation and prevent joint damage in patients with ankylosing spondylitis. It is FDA approved for treating moderate to severe active cases and is administered via subcutaneous injection. Humira helps improve spinal mobility, reduce pain, and enhance overall quality of life.

•             Cosentyx: Novartis

Cosentyx (secukinumab) is an IL 17A inhibitor approved for the treatment of ankylosing spondylitis. It targets a key cytokine involved in inflammation and structural damage. Cosentyx is indicated for patients with active disease and is known for its rapid symptom relief, long term spinal protection, and favourable safety profile.

 

Ankylosing Spondylitis: Emerging Therapies:

• KY1005: It is a monoclonal antibody targeting OX40 ligand, designed to modulate the immune system's overactivity. Currently in clinical trials for autoimmune disorders, it has shown potential in treating ankylosing spondylitis by reducing inflammation and T cell activation, especially in patients unresponsive to conventional biologics like TNF or IL 17 inhibitors.

 

• Abivertinib: It is a Bruton’s tyrosine kinase (BTK) inhibitor under investigation for autoimmune diseases, including ankylosing spondylitis. It aims to suppress aberrant B cell signaling and inflammatory pathways. The therapy could offer a novel mechanism of action for patients with inadequate responses to TNF inhibitors and other biologics.

 

Ankylosing Spondylitis Market Outlook:

• The ankylosing spondylitis market includes the diagnosis, management, and treatment of a chronic inflammatory disease that primarily affects the spine and sacroiliac joints. The market encompasses biologic therapies, NSAIDs, and emerging drugs aimed at reducing inflammation, managing symptoms, and improving long-term mobility and quality of life.
• Key drivers include the rising prevalence of ankylosing spondylitis, increased awareness of autoimmune diseases, advancements in biologic therapies like TNF and IL 17 inhibitors, and a growing demand for early and effective treatment options to prevent disease progression and improve functional outcomes in affected individuals.
• Opportunities lie in the expansion of healthcare access in emerging markets, the development of novel biologics and biosimilars, increasing clinical trials for targeted therapies, and the rising use of telemedicine for chronic disease management. These trends are expected to enhance patient outcomes and support market expansion globally.
• Governments are supporting autoimmune disease care by funding awareness campaigns, offering subsidies for high cost biologic treatments, expanding access to specialist care, and integrating ankylosing spondylitis management into national healthcare programs to ensure better outcomes and reduce long term disability.
• High cost and limited access to biologics remain a key challenge in treatment adoption.
• The market is projected to grow steadily, driven by increased diagnosis rates and greater acceptance of biologic therapies.

 

Ankylosing Spondylitis Market Segmentation:

By Drug Class:

• Non Steroidal Anti Inflammatory Drugs
• TNF Inhibitors
• Others

 

 

 

TNF Inhibitors hold the largest share in the ankylosing spondylitis market due to their high efficacy in reducing inflammation, preventing spinal damage, and improving patient quality of life. Their strong clinical outcomes and wide adoption as first-line biologics have made them the most preferred and widely prescribed treatment option globally.

 

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

 

 

Hospital Pharmacies dominate the market due to the requirement for biologic drugs like TNF inhibitors to be administered under medical supervision. These settings ensure proper handling, dosing, and patient monitoring. Additionally, hospitals treat a higher volume of moderate-to-severe cases, contributing to the higher prescription and distribution rates in this channel.

 

Regional Segment Analysis of the Ankylosing Spondylitis Market:

North America holds the largest share of the ankylosing spondylitis market due to its advanced healthcare infrastructure, early adoption of biologics, and high awareness among patients and providers. The strong presence of pharmaceutical giants, favourable reimbursement systems, and continuous investment in research and development have further solidified the region's dominance. Additionally, a significant number of diagnosed patients and routine screening practices contribute to high treatment demand.

 

Asia Pacific is the fastest growing region in the ankylosing spondylitis market, fueled by rising healthcare expenditures, increasing awareness of autoimmune disorders, and improved access to biologic therapies. Expanding healthcare infrastructure, a large undiagnosed patient base, and growing acceptance of advanced treatments are accelerating market growth. Government initiatives and growing investment from international pharmaceutical companies are also playing a key role in boosting regional expansion and treatment accessibility.

 

Ankylosing Spondylitis Market Key Companies:

• AbbVie
• Novartis
• Pfizer
• Eli Lilly
• Johnson & Johnson
• Merck & Co.
• UCB Pharma
• Amgen
• Bristol Myers Squibb
• Roche
• AstraZeneca
• Boehringer Ingelheim
• Takeda
• Biogen
• Sanofi
• Others

 

Ankylosing Spondylitis Therapeutics Market Report Scope:

• The Ankylosing Spondylitis therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into Ankylosing Spondylitis’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging Ankylosing Spondylitis therapies is provided, including an evaluation of new treatments expected to influence the current Ankylosing Spondylitis treatment market landscape.
• The report includes a detailed review of the Ankylosing Spondylitis therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient Based Ankylosing Spondylitis Market Forecasting report offers valuable insights into trends shaping the global Ankylosing Spondylitis market, helping to develop effective business strategies.

 

Ankylosing Spondylitis Treatment Market Report Insights:

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Ankylosing Spondylitis Therapeutic Approaches in Ankylosing Spondylitis
• Review Of Drugs in Development for Ankylosing Spondylitis
• Market, Growth, and Trends in Ankylosing Spondylitis
• Market Opportunities in Ankylosing Spondylitis Treatment
• Effects Of Future Therapies on Ankylosing Spondylitis Treatment.

 

Ankylosing Spondylitis Treatment Market Report Key Strengths

• 15 Years Ankylosing Spondylitis Market Forecast
• Global Coverage
• Ankylosing Spondylitis Epidemiology Segmentation
• Key Cross Competition

 

Ankylosing Spondylitis Treatment Market Report Assessment

• Present Practices in the Ankylosing Spondylitis Treatment Market
• Review of Investigational Ankylosing Spondylitis Drugs
• Attractiveness of the Ankylosing Spondylitis Drug Market
• Ankylosing Spondylitis Market Drivers
• Ankylosing Spondylitis Market Barriers
• SWOT
• Attribute Analysis

 

Market Segment:

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Ankylosing Spondylitis market based on the following segments:

 

Global Ankylosing Spondylitis Market, By Drug Class

• Non Steroidal Anti Inflammatory Drugs
• TNF Inhibitors
• Others

 

Global Ankylosing Spondylitis Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Ankylosing Spondylitis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa